Investor Contacts Media Contact
Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice Josh Gitelson, Sr. President-Investor Director-Global Relations & Treasury Communications (781) 356-9763 (781) 356-9776 [email protected]… [email protected] David Trenk, Sr. Manager-Investor Relations (203) 733-4987 [email protected]
- Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter of fiscal 2027, which ended September 26, 2026:
2nd Quarter 2027 Year-to-Date 2027 n Revenue, increase $358 million, 9% $697 million, 8% n Organic(1)revenue increase 10.0% 8.0% n Earnings per diluted share $1.00 $1.72 n Adjusted earnings per diluted $1.35 $2.49 share n Cash flow from operating $128 million $180 million activities n Free cash flow $104 million $143 million
__________ (1) Excludes the impacts of currency fluctuation and the exit of certain liquid solution products. Chris Simon, Haemonetics’ CEO, stated: “Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”
Second quarter fiscal 2027 revenue was $357.8 million, up 9.3% compared with the second quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:
Second Quarter Fiscal 2027 Reported -Dollars in Millions Apheresis $204.8 12.6% MedSurg $153.0 5.1% Total net revenue $357.8 9.3%
1 Gross margin was 61.7% in the second quarter of fiscal 2027, compared with 59.5% in the second quarter of fiscal 2026. The primary drivers of the increase in the gross margin percentage included tariffs refunded, the continued transformation of the product portfolio to higher-margin offerings and the absence of amortization of fair value inventory step-up. Operating expenses were $145.8 million, up $9.5 million, or 7.0%, compared with the second quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $75.1 million and a 21.0% operating margin in the second quarter of fiscal 2027, compared with operating income of $58.5 million and a 17.9% operating margin in the second quarter of fiscal 2026. The effective income tax rate was 26.3% in the second quarter of fiscal 2027, compared with 24.6% in the second quarter of fiscal 2026. The increase in the effective income tax rate was primarily due to valuation allowances recorded against deferred tax assets in jurisdictions with losses from recent acquisitions. Second quarter fiscal 2027 net income and earnings per diluted share were $46.3 million and $1.00, respectively, compared with $38.7 million and $0.81, respectively, in the second quarter of fiscal 2026.
Second quarter organic revenue growth was 10.0% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:
Second Quarter Fiscal 2027 Organic Apheresis 13.6% MedSurg 5.5% Total net revenue 10.0%
Second quarter fiscal 2027 adjusted gross margin was 61.9%, up 140 basis points compared with the prior year period. The primary drivers of the increase in the adjusted gross margin percentage included tariffs refunded and the continued transformation of the product portfolio to higher-margin offerings, partially offset by foreign currency fluctuations.
Adjusted operating expenses were $127.6 million, up $16.8 million, or 15.2%, compared with the second quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the second quarter of fiscal 2027 was $94.1 million, up $6.8 million, or 7.8%, compared with the second quarter of fiscal 2026. Adjusted operating margin was 26.3%, down 40 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the second quarter of fiscal 2027 was 24.7%, which was flat when compared with 24.7% in the second quarter of fiscal 2026.
Second quarter fiscal 2027 adjusted net income was $62.6 million, up $2.3 million, or 3.8%, and adjusted earnings per diluted share was $1.35, up 6.3%, each when compared with the same period of fiscal 2026.
Cash on hand as of September 26, 2026 was $260.7 million, an increase of $15.3 million since the end of fiscal 2026, primarily driven by cash flow provided from operating activities, partially offset by cash outflows for the repayment of revolving credit facility borrowings, capital expenditures and contingent consideration payments. 2 Second quarter fiscal 2027 cash flow from operating activities was $128.1 million, up $16.8 million, and free cash flow was $103.8 million, up $15.1 million, each when compared with the same period of fiscal 2026. The primary driver of increased operating cash flow as compared to the same period of fiscal 2026 was favorable working capital adjustments driven by the timing of payments made and cash collections. Free cash flow was impacted by higher capital expenditures, which was partially offset by lower non-cash transfers from Haemonetics equipment.
Total Company Previous Guidance Current Guidance Reported Revenue 5 - 8% 8 - 11% 53rd week impact -~2% -~2% Strategic exits(1) ~1% ~1% Currency impact 0 - 1% 0 - 1% Organic Revenue(2) 4 - 7% 6 - 9% Adjusted operating 50 – 100 bps expansion 0 – 50 bps expansion margin YoY YoY Adjusted earnings per Comparable to reported Comparable to reported diluted share revenue growth revenue growth Free cash flow ~80% >80% conversion(3)
(2) Previous guidance includes approximately low- to mid-single-digit growth in Apheresis and mid-single digit growth in MedSurg. Current guidance includes high-single-digit growth in Apheresis and mid-single digit growth in MedSurg. Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance.
(3) Free cash flow conversion is calculated as free cash flow divided by adjusted net income.
The Co mpany will host a conference call with investors and analysts to discuss second quarter fiscal 2027 results on Thursday, November 5, 2026 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register-conf.media- server.com/register/BIf24df80f681345eb86967db309c34804 . Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media- server.com/mmc/p/kf8g7up6 .
The Company has also provided a supplemental earnings presentation for its second quarter of fiscal 2027, which is available on its website and can be found at the following direct link: https://haemonetics.gcs-web.com/static- files/96c2477d-9271-40e4-93f2-f3691621b414 . 3
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com .
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to th e Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward- looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company’s ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company’s ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward- looking statements. 4
This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of currency fluctuation and the exit of certain liquid solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition and integration related costs, certain tax settlements, unusual or infrequent and material litigation-related charges, equity method losses, impairment of intangible assets and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjust ments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com . The Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow conversion guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs, impairment charges and capital expenditures, is inherently uncertain and difficult to predict and is unavailable without unreasonable effor ts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance. 5
(4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit.
(5) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit. 7
Condensed Consolidated Statements of Cash Flows September 26, September 27, (Unaudited) Six Months Ended 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Dollars in Thousands Cash Flows from Operating Activities: Net income $ 79,315 $ 72,715 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 54,871 57,013 amortization Amortization of fair value — 4,491 inventory step-up Share-based compensation 19,539 16,901 expense Impairment of intangible — 8,584 assets Deferred income 3,234 -3,956 taxes Change in other non-cash 5,389 2,361 operating activities Change in operating assets and liabilities: Change in accounts -8,064 -3,702 receivable, net Change in inventories, 978 25,058 net Change in prepaid income 2,428 3,136 taxes Change in other assets and -18,277 -23,688 other liabilities Change in accounts payable and 41,010 -30,197 accrued expenses Net cash provided by 180,423 128,716 operating activities Cash Flows from Investing Activities: Capital -22,677 -8,770 expenditures Non-cash transfers from inventory to property, plant -15,657 -29,149 and equipment for Haemonetics equipment Proceeds from sale of 813 417 property, plant and equipment Other -9,000 -25,966 investments Net cash used in investing -46,521 -63,468 activities Cash Flows from Financing Activities: Repayments, net -103,125 -3,125 of borrowings Share — -75,000 repurchases Contingent consideration -17,597 — payments Proceeds from employee stock 5,500 4,001 programs Cash used to net share -3,888 -4,795 settle employee equity awards Other financing -29 -75 activities Net cash used in financing -119,139 -78,994 activities Effect of exchange rates on cash and 509 3,409 cash equivalents Net Change in Cash and Cash 15,272 -10,337 Equivalents Cash and Cash Equivalents at 245,440 306,763 Beginning of the Period Cash and Cash Equivalents at $ 260,712 $ 296,426 End of Period Free Cash Flow Reconciliation: Cash provided by operating $ 180,423 $ 128,716 activities Capital -22,677 -8,770 expenditures Additions to Haemonetics -15,657 -29,149 equipment Proceeds from sale of 813 417 property, plant and equipment Free cash flow $ 142,902 $ 91,214
Full text with the tables
Exhibit 99.1
Investor Contacts Media Contact
Olga Guyette, Vice Josh Gitelson, Sr.
President-Investor Director-Global
Relations & Treasury Communications
(781) 356-9763 (781) 356-9776
[email protected]… [email protected]
David Trenk, Sr.
Manager-Investor
Relations
(203) 733-4987
[email protected]
Haemonetics R
eports Second Quarter and First Half Fiscal 2027 Results;
Updates Fiscal 2027 Guidance
Boston,
MA, November 5, 2026
- Haemonetics Corporation (NYSE: HAE) reported financial results for its second
quarter of fiscal 2027, which ended September 26, 2026:
2nd Quarter 2027 Year-to-Date 2027
n Revenue, increase $358 million, 9% $697 million, 8%
n Organic(1)revenue increase 10.0% 8.0%
n Earnings per diluted share $1.00 $1.72
n Adjusted earnings per diluted $1.35 $2.49
share
n Cash flow from operating $128 million $180 million
activities
n Free cash flow $104 million $143 million
__________
(1) Excludes the impacts of currency fluctuation and the exit of certain liquid
solution products.
Chris Simon, Haemonetics’ CEO, stated: “Our second-quarter and first-half
results reflect significant momentum across our businesses. Expansion of our CSL
relationship and recent innovation milestones in both Apheresis and MedSurg
strengthen our competitive position and create powerful new opportunities. With
multiple catalysts for growth, we are focused on executing for our customers and
translating our momentum into sustained success and shareholder value.”
GAAP RESULTS
Second quarter fiscal 2027 revenue was $357.8 million, up 9.3% compared with the
second quarter of fiscal 2026. Business unit revenue and growth rates compared
with the prior year period were as follows:
Second Quarter Fiscal 2027 Reported
-Dollars in Millions
Apheresis $204.8 12.6%
MedSurg $153.0 5.1%
Total net revenue $357.8 9.3%
1
Gross margin was 61.7% in the second quarter of fiscal 2027, compared with 59.5%
in the second quarter of fiscal 2026. The primary drivers of the increase in the
gross margin percentage included tariffs refunded, the continued transformation
of the product portfolio to higher-margin offerings and the absence of
amortization of fair value inventory step-up. Operating expenses were $145.8
million, up $9.5 million, or 7.0%, compared with the second quarter of fiscal
2026. The increase in operating expenses was driven by higher personnel-related
costs and freight charges. The Company had operating income of $75.1 million and
a 21.0% operating margin in the second quarter of fiscal 2027, compared with
operating income of $58.5 million and a 17.9% operating margin in the second
quarter of fiscal 2026. The effective income tax rate was 26.3% in the second
quarter of fiscal 2027, compared with 24.6% in the second quarter of fiscal
2026. The increase in the effective income tax rate was primarily due to
valuation allowances recorded against deferred tax assets in jurisdictions with
losses from recent acquisitions. Second quarter fiscal 2027 net income and
earnings per diluted share were $46.3 million and $1.00, respectively, compared
with $38.7 million and $0.81, respectively, in the second quarter of fiscal
2026.
ADJUSTED RESULTS
Second quarter organic revenue growth was 10.0% compared with the same period of
fiscal 2026. Year-over-year organic revenue growth rates by business unit were
as follows:
Second Quarter Fiscal 2027
Organic
Apheresis 13.6%
MedSurg 5.5%
Total net revenue 10.0%
Second quarter fiscal 2027 adjusted gross margin was 61.9%, up 140 basis points
compared with the prior year period. The primary drivers of the increase in the
adjusted gross margin percentage included tariffs refunded and the continued
transformation of the product portfolio to higher-margin offerings, partially
offset by foreign currency fluctuations.
Adjusted operating expenses were $127.6 million, up $16.8 million, or 15.2%,
compared with the second quarter of fiscal 2026. The increase in adjusted
operating expenses was driven by higher personnel-related costs and freight
charges. Adjusted operating income for the second quarter of fiscal 2027 was
$94.1 million, up $6.8 million, or 7.8%, compared with the second quarter of
fiscal 2026. Adjusted operating margin was 26.3%, down 40 basis points when
compared with the same period of fiscal 2026. The adjusted income tax rate for
the second quarter of fiscal 2027 was 24.7%, which was flat when compared with
24.7% in the second quarter of fiscal 2026.
Second quarter fiscal 2027 adjusted net income was $62.6 million, up $2.3
million, or 3.8%, and adjusted earnings per diluted share was $1.35, up 6.3%,
each when compared with the same period of fiscal 2026.
BALANCE SHEET AND CASH FLOW
Cash on hand as of September 26, 2026 was $260.7 million, an increase of $15.3
million since the end of fiscal 2026, primarily driven by cash flow provided
from operating activities, partially offset by cash outflows for the repayment
of revolving credit facility borrowings, capital expenditures and contingent
consideration payments.
2
Second quarter fiscal 2027 cash flow from operating activities was $128.1
million, up $16.8 million, and free cash flow was $103.8 million, up $15.1
million, each when compared with the same period of fiscal 2026. The primary
driver of increased operating cash flow as compared to the same period of fiscal
2026 was favorable working capital adjustments driven by the timing of payments
made and cash collections. Free cash flow was impacted by higher capital
expenditures, which was partially offset by lower non-cash transfers from
Haemonetics equipment.
FISCAL 2027 GUIDANCE
The Company updated its previous fiscal 2027 guidance as follows:
Total Company
Previous Guidance Current Guidance
Reported Revenue 5 - 8% 8 - 11%
53rd week impact -~2% -~2%
Strategic exits(1) ~1% ~1%
Currency impact 0 - 1% 0 - 1%
Organic Revenue(2) 4 - 7% 6 - 9%
Adjusted operating 50 – 100 bps expansion 0 – 50 bps expansion
margin YoY YoY
Adjusted earnings per Comparable to reported Comparable to reported
diluted share revenue growth revenue growth
Free cash flow ~80% >80%
conversion(3)
__________
(1) Includes the impact of the exit of certain liquid solution products.
(2) Previous guidance includes approximately low- to mid-single-digit growth in
Apheresis and mid-single digit growth in MedSurg. Current guidance includes
high-single-digit growth in Apheresis and mid-single digit growth in MedSurg.
Organic growth guidance also includes nominal historical pre-acquisition revenue
of Vivasure to provide a comparable view of period-over-period performance.
(3) Free cash flow conversion is calculated as free cash flow divided by
adjusted net income.
WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS
The Co mpany will host a conference call with investors and analysts to discuss
second quarter fiscal 2027 results on Thursday, November 5, 2026 at 8:00 a.m.
ET. The call can be accessed via teleconference at https://register-conf.media-
server.com/register/BIf24df80f681345eb86967db309c34804 . Once registration is
completed, participants will receive a dial-in number along with a personalized
PIN to access the call. While not required, it is recommended that participants
join 10 minutes prior to the event start.
Alternatively, a live webcast of the call can be accessed on Haemonetics’
investor relations website at the following direct link: https://edge.media-
server.com/mmc/p/kf8g7up6 .
The Company has also provided a supplemental earnings presentation for its
second quarter of fiscal 2027, which is available on its website and can be
found at the following direct link: https://haemonetics.gcs-web.com/static-
files/96c2477d-9271-40e4-93f2-f3691621b414 .
3
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the
quality, effectiveness and efficiency of health care. Our Apheresis business
features proprietary technologies designed to enhance safety, yield, donor
satisfaction and operational efficiency for plasma and blood collectors around
the world. Our MedSurg business offers Blood Management Technologies to help
inform treatment decisions and optimize the management of blood products, and
Interventional Technologies, including advanced vascular closure systems and
sensor-guided technologies, designed to drive procedural effectiveness and
elevate the patient experience. To learn more about Haemonetics, visit
www.haemonetics.com .
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking statements in
this press release may include, without limitation, statements regarding (i)
plans and objectives of management for operations of the Company, including
plans or objectives related to th e Company’s strategy for growth; product
development, commercialization and anticipated benefits; regulatory approvals;
the impact of acquisitions and divestitures; market position and expenditures;
and the Company’s market and regional alignment initiative; (ii) estimates or
projections of future financial results, financial condition, capital
expenditures, capital structure or other financial items, including with respect
to the Company’s share repurchase program; and (iii) the assumptions underlying
or relating to any statement described in points (i) and (ii) above.
Such forward-looking statements are not meant to predict or guarantee actual
results, performance, events or circumstances and may not be realized because
they are based upon the Company’s current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to a number of
risks and uncertainties and other influences. Actual results and the timing of
certain events and circumstances may differ materially from those described by
the forward-looking statements as a result of these risks and uncertainties.
Factors that may influence or contribute to the inaccuracy of the forward-
looking statements or cause actual results to differ materially from expected or
desired results may include, without limitation, availability and demand for the
Company’s products; the Company’s ability to successfully develop and market new
products and technologies; the impact of competitive products and pricing;
product quality; disruptions caused by cybersecurity events; any failure to
realize the anticipated strategic benefits and opportunities from acquisitions
and divestitures; pricing pressures resulting from trends toward healthcare cost
containment and the effect of industry consolidation; manufacturing,
distribution and supply chain disruptions and cost increases; the Company’s
ability to implement as planned and realize estimated cost savings from the
market and regional alignment initiative; the effects of global economic and
political conditions, including changing trade and tariff policies and
inflationary pressures; regulatory uncertainties, including in the receipt or
timing of regulatory approvals, and the impact of changes in global regulatory
conditions; indebtedness incurred by the Company, including the conditional
conversion feature of its convertible notes; the Company’s ability to protect
its intellectual property; litigation; and the impact of share repurchases on
the Company’s stock price and volatility as well as the effect of short-term
price fluctuations on the share repurchase program’s effectiveness. These and
other factors are identified and described in more detail in the Company’s
periodic reports and other filings with the U.S. Securities and Exchange
Commission (the “SEC”). The Company does not undertake to update these forward-
looking statements.
4
MANAGEMENT’S USE OF NON-GAAP MEASURES
This press release contains financial measures that are considered “non-GAAP”
financial measures under applicable SEC rules and regulations. Management uses
non-GAAP measures to monitor the financial performance of the business, make
informed business decisions, establish budgets and forecast future results.
Performance targets for management are also based on certain non-GAAP financial
measures. These non-GAAP financial measures should be considered supplemental
to, and not a substitute for, the Company’s reported financial results prepared
in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures
have been provided to assist investors in evaluating the performance of the
Company’s core operations and provide a baseline for analyzing trends in the
Company’s underlying businesses. We strongly encourage investors to review the
Company’s financial statements and publicly-filed reports in their entirety and
not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of
currency fluctuation and the exit of certain liquid solution products. Adjusted
gross profit, adjusted operating expenses, adjusted operating income, adjusted
interest and other income/expense, adjusted provision for income taxes, adjusted
net income and adjusted earnings per diluted share exclude restructuring costs,
restructuring related costs, digital transformation costs, amortization of
acquired intangible assets, amortization of fair value inventory step-up,
acquisition and integration related costs, certain tax settlements, unusual or
infrequent and material litigation-related charges, equity method losses,
impairment of intangible assets and remeasurement of contingent consideration.
Adjusted net income and adjusted earnings per diluted share also exclude the tax
impact of these items. The adjust ments to provision for income taxes are
calculated based on the jurisdictions in which pre-tax adjustments occurred.
Free cash flow is defined as cash provided by operating activities less capital
expenditures and additions to Haemonetics equipment, net of the proceeds from
the sale of property, plant and equipment. Because non-GAAP financial measures
are not standardized, it may not be possible to compare these financial measures
to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most
comparable GAAP measure are included at the end of the financial sections of
this press release as well as on the Company’s website at www.haemonetics.com .
The Company does not attempt to provide reconciliations of forward-looking
adjusted operating margin guidance, adjusted earnings per diluted share guidance
or free cash flow conversion guidance to the comparable GAAP measures because
the combined impact and timing of recognition of certain potential charges or
gains, such as restructuring costs, impairment charges and capital expenditures,
is inherently uncertain and difficult to predict and is unavailable without
unreasonable effor ts. In addition, the Company believes such reconciliations
would imply a degree of precision and certainty that could be confusing to
investors. Such items could have a substantial impact on GAAP measures of the
Company’s financial performance.
5
T… Six
M… Mo…
E… En…
… 9… 9/…
… (… (D…
… a… and
… S… Sh…
… in in
… T… Th…
… E… Ex…
… P… Per
… S… I… Sh… In…
… D… 9/… % Da… 9… %
──────────────────────────────────────────────────────────────────────────────
… $ 3… $ 32… 9… $ 69… $ 6… 7.…
…
…
… 1… 13… 3… 27… 2… 4.…
…
…
… 2… 19… 1… 42… 3… 9.…
…
…
… 1… 14… 1… 33… 3… 6.…
…
…
… 1… 10… 1… 23… 2… 11…
…
…
…
…
… 1… 11… (… 20… 2… (8…
…
…
…
… — 8,… (… — 8… (1…
…
…
…
… 1… 13… 7… 29… 2… 6.…
…
… 7… 58… 2… 13… 1… 18…
…
…
…
… -… -7… 7… -2… -… 39…
…
…
…
…
… 6… 51… 2… 11… 9… 14…
…
…
…
…
… 1… 12… 3… 31… 2… 31…
…
…
… $ 4… $ 38… 1… $ 79… $ 7… 9.…
…
…
…
…
… $ 1… $ 0.… 2… $ 1.… $ 1… 13…
…
…
…
…
…
…
…
… 4… 47… 45… 4…
… 4… 47… 46… 4…
… I… In…
… % %
… 61… % 5… % 2… 6… % 59… % 1.…
…
…
… 4.8 % 4… % 0… 4… % 4.8 % —%
…
…
… 33… % 3… % 2… 3… % 32… % 1.…
…
…
… 21… % 1… % 3… 1… % 17… % 1.…
…
…
…
… 17… % 1… % 1… 1… % 14… % 0.…
…
…
…
… 12… % 1… % 1… 1… % 11… % 0.…
…
6
…
…
…
… T…
… M…
… E…
… 9…
… (…
… in R… C… S… O…
… T… 9… g… i… E… g…
──────────────────────────────────────────────────────────────────────────────
… $ 1… $ 1… 1… % -0… % -0… % 17… %
… 4… 4… — % -0… % — % 0.2 %
… $ 2… $ 1… 1… % -0… % -0… % 13… %
… $ 6… $ 5… 2… % -0… % — % 3.2 %
…
…
… 9… 8… 7… % — % — % 7.0 %
…
… $ 1… $ 1… 5… % -0… % — % 5.5 %
…
… $ 3… $ 3… 9… % -0… % -0… % 10… %
…
S…
M…
E…
9… 9… R… C… S… O…
g… i… E… g…
-…
in
T…
…
…
…
…
… $ 3… $ 2… 1… % -0… % -0… % 12… %
… 7… 7… -… % 0.1 % — % -1… %
… $ 3… $ 3… 9… % -0… % -0… % 9.8 %
… $ 1… $ 1… 2… % -0… % — % 3.0 %
…
…
… 1… 1… 7… % 0.2 % — % 7.5 %
…
… $ 3… $ 2… 5… % -0… % — % 5.7 %
…
… $ 6… $ 6… 7… % -0… % -0… % 8.0 %
…
__________
(1) Includes the impact of the exit of certain liquid solution products.
(2) Includes nominal historical pre-acquisition revenue of Vivasure.
(3) Other includes blood collection and processing devices and disposables.
(4) Interventional Technologies includes Vascular Closure, Sensor Guided
Technologies and Esophageal Protection product lines of the MedSurg business
unit.
(5) Blood Management Technologies includes Hemostasis Management, Cell Salvage
and Transfusion Management product lines of the MedSurg business unit.
7
Condensed
Consolidated
Balance Sheets September 26,
(Unaudited) 2026 March 28, 2026
──────────────────────────────────────────────────────────────────────────────
-Dollars in
Thousands
Assets
Cash and cash $ 260,712 $ 245,440
equivalents
Accounts 224,952 216,855
receivable, net
Inventories, net 305,006 306,370
Other current 64,857 66,214
assets
Total current 855,527 834,879
assets
Property, plant 307,921 305,761
& equipment, net
Intangible 426,364 447,655
assets, net
Goodwill 657,104 656,368
Other assets 163,689 151,262
Total assets $ 2,410,605 $ 2,395,925
Liabilities &
Stockholders'
Equity
Short-term debt
& current $ 9,643 $ 5,015
maturities
Other current 291,195 277,584
liabilities
Total current 300,838 282,599
liabilities
Long-term debt 1,114,118 1,219,565
Other long-term 97,152 97,441
liabilities
Stockholders' 898,497 796,320
equity
Total
liabilities & $ 2,410,605 $ 2,395,925
stockholders'
equity
8
Condensed
Consolidated
Statements of
Cash Flows September 26, September 27,
(Unaudited) Six Months Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
-Dollars in
Thousands
Cash Flows from
Operating
Activities:
Net income $ 79,315 $ 72,715
Adjustments to
reconcile net
income to
net cash
provided by
operating
activities:
Depreciation
and 54,871 57,013
amortization
Amortization of
fair value — 4,491
inventory
step-up
Share-based
compensation 19,539 16,901
expense
Impairment of
intangible — 8,584
assets
Deferred income 3,234 -3,956
taxes
Change in other
non-cash 5,389 2,361
operating
activities
Change in
operating
assets and
liabilities:
Change in
accounts -8,064 -3,702
receivable, net
Change in
inventories, 978 25,058
net
Change in
prepaid income 2,428 3,136
taxes
Change in other
assets and -18,277 -23,688
other
liabilities
Change in
accounts
payable and 41,010 -30,197
accrued
expenses
Net cash
provided by 180,423 128,716
operating
activities
Cash Flows from
Investing
Activities:
Capital -22,677 -8,770
expenditures
Non-cash
transfers from
inventory to
property, plant -15,657 -29,149
and equipment
for
Haemonetics
equipment
Proceeds from
sale of 813 417
property, plant
and equipment
Other -9,000 -25,966
investments
Net cash used
in investing -46,521 -63,468
activities
Cash Flows from
Financing
Activities:
Repayments, net -103,125 -3,125
of borrowings
Share — -75,000
repurchases
Contingent
consideration -17,597 —
payments
Proceeds from
employee stock 5,500 4,001
programs
Cash used to
net share -3,888 -4,795
settle employee
equity awards
Other financing -29 -75
activities
Net cash used
in financing -119,139 -78,994
activities
Effect of
exchange rates
on cash and 509 3,409
cash
equivalents
Net Change in
Cash and Cash 15,272 -10,337
Equivalents
Cash and Cash
Equivalents at 245,440 306,763
Beginning
of the Period
Cash and Cash
Equivalents at $ 260,712 $ 296,426
End of
Period
Free Cash Flow
Reconciliation:
Cash provided
by operating $ 180,423 $ 128,716
activities
Capital -22,677 -8,770
expenditures
Additions to
Haemonetics -15,657 -29,149
equipment
Proceeds from
sale of 813 417
property, plant
and equipment
Free cash flow $ 142,902 $ 91,214
9
…
…
…
…
… … …
… … … E…
… … … … p…
… … … … … … d…
… … … … … … s…
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … $ -… $ 1… $ … $ …
— … … — 2… … …
… … … -2 91 … …
… 7 … — -… … —
… — … — — … —
— … … — 1… … …
— … … — — … —
— … … — 1… … …
— — — 1… 3… … …
— — — — 1 … —
$ … $ … $ … $ -… $ 2… $ … $ …
… % … % … % 1… %
… … E…
… … … … … … p…
… … … … … … d…
… … … … s…
…
…
…
…
…
…
…
…
$ … $ … $ … $ -… $ 1… $ … $ …
— … … — 2… … …
… — … — 5… … …
… … … — 3… … …
… … … — 75 … —
… … … — 12 … —
— … … — 1… … …
— … … — 53 … —
— … … — 2… … …
— … … — -… … —
$ … $ … $ … $ -… $ 1… $ … $ …
… % … % … % 1… %
10
…
…
…
…
… … …
… … … E…
… … … … … p…
… … … … … … d…
… … … … … … s…
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … $ -… $ 3… $ … $ …
— … … — 4… … …
… … … -2 -… … …
… … … — 5… … …
… … … — — … —
— … … — 2… … …
— … … — — … …
— … … — 1… … …
— — — 2… 5… … …
— — — — -… … …
$ … $ … $ … $ -… $ 3… $ … $ …
… % … % … % 1… %
… … E…
… … … … … … p…
… … … … … … d…
… … … … s…
… …
…
…
…
…
…
…
…
$ … $ … $ … $ -… $ 2… $ … $ …
— … … — 5… … …
… — … — 1… … …
… … … 2… 1… … …
… … … — 3… … …
… … … — 21 … —
— … … — 2… … …
— … … — 2… … …
— … … — 2… … …
— … … — -… … —
$ … $ … $ … $ -… $ 3… $ … $ …
… % … % … % 1… %
11